PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti,

PROCEPT BioRobotics is facing a securities-fraud class action tied to allegedly undisclosed inventory issues and an approximately 18% decline in its share price. The litigation and inventory-related disclosure concerns create material reputational and financial risk for the medical-device company, with the primary market impact likely concentrated in its stock.